Table 1.

Guidelines for lipid management in peripheral arterial disease.

Guideline source	Year	LDL-C	HDL-C	Triglycerides	Ref.
ACCF/AHA	2011	Class 1: LDL <100 mg/dl, for all patients with PAD using HMG-CoA reductase inhibitor (statin) Class 2a: LDL <70 mg/dl, for those at high risk of ischemic events	Class 2a: low HDL, consider treatment with fibric acid derivative	Class 2a: elevated triglycerides, consider treatment with fibric acid derivative	[28]
TASC II	2007	LOE A: LDL <100 mg/dl, for all patients with PAD LOE B: LDL <70 mg/dl, for patients with atherosclerosis in other territories LOE A: statin drugs should be the primary agent used	LOE B: low HDL, consider treatment with niacin or fibrates	LOE B: elevated triglycerides, consider treatment with fibrates	[27]
ESC	2011	Class 1: LDL <2.5 mmol/l (100 mg/dl), for all patients with PAD Class 1: Optimal LDL <1.8 mmol/l (<70 mg/dl) Class 1: Goal >50% LDL reduction, if target level cannot be reached	Not addressed in guidelines	Not addressed in guidelines	[29]

ACCF: American College of Cardiology Foundation; AHA: American Heart Association; ESC: European Society of Cardiology; LOE: Level of evidence; PAD: Peripheral arterial disease; TASC II: Inter-Society Consensus for the Management of Peripheral Arterial Disease.